Clinical Trial Update: Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Abiraterone Acetate versus an Aromatase Inhibitor in postmenopausal ER-positive operable breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Aromatase inhibitor (unspecified) (aromatase inhibitor)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer | Phase 2 | Status: WITHDRAWN